# US 2021/0079384 A1 · Non-invasive detection of response to a targeted therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079384 A1
- Document ID: US20210079384A1
- Status: Published application
- Kind: A1
- Application number: 17/047,013
- Filed: 2019-04-12
- Published: 2021-03-18
- Earliest claimed: 2018-04-13
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Victor E. Velculescu; Jillian A. Phallen; Alessandro Leal; Hatim Husain
- Web page: https://patentgrep.com/patent/US20210079384A1

## CPC

- C12N 15/1072: {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein are method of determining the efficacy of targeted therapy in a subject by detecting changes in levels of cell-free tumor load (cfTL). In some aspects, the efficacy of targeted therapy is determined a very short time after the targeted therapy is administered. Also provided herein are method of determining resistance to a targeted therapy in a subject by detecting changes in levels of cell-free tumor load (cfTL).

## Claims

### Claim 1

A method of determining the efficacy of a targeted therapy in a subject having cancer, comprising:
detecting a first cell-free tumor load (cfTL) in a biological sample isolated from the subject at a first time point;
detecting a second cfTL in a biological sample obtained from the subject at a second time point, wherein the subject has received at least one dose of the targeted therapy between the first time point and the second time point; and
identifying the targeted therapy as being effective in the subject when the subject exhibits a second cfTL that is reduced as compared to the first cfTL.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
detecting the first cfTL comprises detecting a first level of the at least one genetic alteration in circulating tumor DNA (ctDNA) in the biological sample isolated from the subject at the first time point, wherein the first cfTL corresponds to the first level of the at least one genetic alteration; and
detecting the second cfTL comprises detecting a second level of the at least one genetic alteration in circulating tumor DNA (ctDNA) in the biological sample isolated from the subject at the second time point, wherein the second cfTL corresponds to the second level of the at least one genetic alteration.

### Claim 3

(canceled)

### Claim 4 (depends on 3)

The method of claim 3, wherein detecting the first level of the at least one genetic alteration, detecting the second level of the at least one genetic alteration, or both comprises:
extracting cell-free DNA from blood;
ligating a low complexity pool of dual index barcode adapters to the cell-free DNA to generate a plurality of barcode adapter-ligated cell-free DNA segments;
capturing the plurality of barcode adapter-ligated cell-free DNA segments;
sequencing the plurality of captured barcode adapter-ligated cell-free DNA segments;
aligning the sequenced plurality of captured barcode adapter-ligated cell-free DNA segments to a reference genome; and
identifying sequence alterations using aligned sequences of multiple distinct molecules containing identical redundant changes.

### Claim 5 (depends on 2)

The method of claim 2, wherein the at least one genetic is a mutation is in an EGFR gene, an ERBB2 gene, or both.

### Claim 6 (depends on 2)

The method of claim 2, wherein the at least one genetic alteration is a T790M mutation in the EGFR gene.

### Claim 7 (depends on 2)

The method of claim 2, wherein the second level of the at least one genetic alteration of ctDNA is at least about 90% lower than the first level of the at least one genetic alteration of ctDNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein:
detecting the first cfTL comprises detecting a first level of aneuploidy in the biological sample isolated from the subject at the first time point, wherein the first cfTL corresponds to the first level of aneuploidy; and
detecting the second cfTL comprises detecting a second level of aneuploidy in the biological sample isolated from the subject at the second time point, wherein the second cfTL corresponds to the second level of aneuploidy.

### Claim 9 (depends on 8)

The method of claim 8, wherein detecting the first level of aneuploidy, detecting the second level of aneuploidy, or both comprises:
performing digital karyotyping, next generation sequencing, array-based methods, and combinations thereof.

### Claim 10 (depends on 8)

The method of claim 8, comprising:
a) extracting a first sample of cell-free DNA from blood at the first time point;
ligating a low complexity pool of dual index barcode adapters to the first cell-free DNA sample to generate a first plurality of barcode adapter-ligated cell-free DNA segments;
capturing the first plurality of barcode adapter-ligated cell-free DNA segments;
eluting the non-captured cell-free DNA to generate a first non-captured cell-free DNA sample;
detecting the first level of aneuploidy in the first non-captured non-capture cell-free DNA; and
b) extracting a second sample of cell-free DNA from blood at the second time point;
ligating a low complexity pool of dual index barcode adapters to the cell-free DNA to generate a plurality of barcode adapter-ligated cell-free DNA segments;
capturing the plurality of barcode adapter-ligated cell-free DNA segments;
eluting the non-captured cell-free DNA to generate a second non-captured cell-free DNA sample;
detecting the second level of aneuploidy in the second non-captured non-capture cell-free DNA.

### Claim 11 (depends on 8)

The method of claim 8, wherein a second level of at least one genetic alteration in circulating tumor DNA (ctDNA) in the biological sample isolated from the subject at the first time point is not substantially different than a first level of the at least one genetic alteration in circulating tumor DNA (ctDNA) in the biological sample isolated from the subject at the first time point.

### Claim 12 (depends on 1)

The method of claim 1, wherein the biological sample obtained from the subject at the first time point, the second time point, or both comprises blood, plasma, serum, urine, cerebrospinal fluid, saliva, sputum, broncho-alveolar lavage, bile, lymphatic fluid, cyst fluid, stool, uterine lavage, vaginal fluids, ascites, and combinations thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the targeted therapy is a kinase inhibitor.

### Claim at position 14

14-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject has been previously administered a different treatment or targeted therapy and the different treatment or targeted therapy was determined not to be therapeutically effective.

### Claim 17

(canceled)

### Claim 18 (depends on 17)

The method of claim 17, further comprising administering a therapeutic intervention to the subject.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of: a head and neck cancer, a central nervous system cancer, a lung cancer, a mesothelioma, an esophageal cancer, a gastric cancer, a gall bladder cancer, a liver cancer, a pancreatic cancer, a melanoma, an ovarian cancer, a small intestine cancer, a colorectal cancer, a breast cancer, a sarcoma, a kidney cancer, a bladder cancer, a uterine cancer, a cervical cancer, and a prostate cancer.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cancer is a lung cancer, and the lung cancer is non-small cell lung cancer.

### Claim 22 (depends on 20)

The method of claim 20, wherein the cancer comprises a population of cancer cells that harbor an EGFR mutation, a ERBB2 mutation, or both.

### Claim 23 (depends on 1)

The method of claim 1, the second time point is between about 1 week to about 4 weeks after the first time point.

### Claim at position 23

24-25. (canceled)

### Claim 26

A method of determining response to a targeted therapy in a subject having cancer, comprising:
detecting a first level of at least one genetic alteration in circulating tumor DNA (ctDNA) in a biological sample isolated from the subject at a first time point;
detecting a second level of the at least one genetic alteration in circulating tumor DNA (ctDNA) in a biological sample obtained from the subject at a second time point, wherein the subject has received at least one dose of the targeted therapy between the first time point and the second time point; and
identifying the subject as responding to the targeted therapy when the second level of the at least one genetic alteration is substantially increased as compared to the first level of the at least one genetic alteration.

### Claim at position 25

27-28. (canceled)

### Claim 29

A method of determining poor efficacy of a targeted therapy in a subject having cancer, comprising:
detecting a first cell-free tumor load (cfTL) in a biological sample isolated from the subject at a first time point;
detecting a second cfTL in a biological sample obtained from the subject at a second time point, wherein the subject has received at least one dose of the targeted therapy between the first time point and the second time point; and
identifying the targeted therapy as having poor efficacy in the subject when the subject exhibits a second cfTL that is not substantially reduced as compared to the first cfTL.

### Claim at position 27

30-34. (canceled)
